$CCNE

CNB Financial Corporation Q1 2026 Earnings: Revenue Misses $83.3 Million

CNB Financial Corporation (CCNE) reported Q1 2026 diluted EPS of $0.88, beating estimates, but revenue of $83.3M missed expectations. Net income rose to $26M from $10.4M YoY. Shares were up 0.89% post-earnings. The company attributed growth to its 2025 ESSA acquisition, but noted sequential revenue decline due to commercial real estate payoffs.

Original reporting
Published Sep 15, 2026, 8:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CNB Financial Corporation Q1 2026 Earnings: Revenue Misses $83.3 Million — source image
Decision brief

The 30-second read

$CCNENeutralMed
01

Why it matters

The earnings release provides the first public disclosure of Q1 2026 financials, highlighting an EPS beat and revenue shortfall, which may influence short-term trading decisions.

02

Market read

Earnings beat offers a modest bullish trigger, but revenue miss and loan declines introduce downside risk.

03

What to watch

ESSA acquisition synergies and lower noninterest expense growth could boost future earnings.

Relevance 7/10Novelty 8/10Timing: post-earnings release

Background

CNB Financial (CCNE) is a regional bank with $1B market cap, recently expanded via the 2025 ESSA Bancorp acquisition.

Company-level read

Ticker impact

$CCNENeutralMedium confidence
Context

Q1 2026 earnings beat EPS estimate but missed revenue, shares up 0.89% on release.

Expected impact

modest upside of 2-3% if market focuses on EPS beat, downside risk if revenue concerns dominate

Evidence & confidence

EPS beat is a positive catalyst, but revenue miss and sequential loan decline temper enthusiasm.

Market effects

Regional banking sector may see similar pressure on loan growth and revenue guidance.

Pennsylvania and Mid-Atlantic banking stocks could experience modest volatility.

Limited; primarily a US regional bank story.

Counterpoint

Revenue miss may be overstated; focus on improving efficiency ratio and higher net interest margin.

Key entities

  • Michael Peduzzi

    President & CEO of CNB Financial, provided commentary on earnings.

Related articles

$CCNEMed

CNB FINANCIAL CORPORATION REPORTS SECOND QUARTER 2026 RESULTS

CNB FINANCIAL CORP/PA (CCNE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ccne7-23x2699x1.htm EX-99.1 Document News Release Contact: Tito L. Lima Treasurer (814) 765-9621 FOR IMMEDIATE RELEASE CNB FINANCIAL CORPORATION REPORTS SECOND QUARTER 2026 RESULTS Clearfield, Pennsylvania – July 23, 2026 CNB Financial Corporation (“Corporation”) (NASDA

$GSMedAI 8/10

Goldman Sachs is booming, Wells Fargo is feeling the squeeze — what should investors watch next?

Goldman Sachs and Citigroup beat earnings expectations, while Wells Fargo reported softer revenue and JPMorgan missed profit targets. Goldman's equity trading surged 72%, driving its revenue and net income up. JPMorgan saw a 49% increase in equity markets revenue but weaker fixed-income trading. Citi's earnings rose 40%, and Wells Fargo increased credit provisions, highlighting the impact of higher rates on banks.

$GSHighAI 9/10

The Goldman Sachs Group Inc (GS) (Q3 2026) Earnings Call Highlights: Record Advisory

Goldman Sachs (GS) reported Q3 2026 net revenues of $18.7B, with record advisory revenues and 72% YoY growth in equities. Asset management revenues rose 14% YoY. Challenges include geopolitical tensions, inflation, and credit quality concerns. CEO David Solomon addressed succession plans, market structure, and AI financing risks. The company maintains a strong capital buffer and expects active Q4 trading. GS's durable revenues now represent 45% of YTD revenues.

$JNJHighAI 9/10

Johnson & Johnson (JNJ) (Q3 2026) Earnings Call Highlights: Talc Settlement Weighs

Johnson & Johnson (JNJ) reported Q3 2026 operational sales growth of 6%, exceeding expectations. Innovative Medicine grew 7.9%, with key products like TREMFYA and CARVYKTI showing strong sales. The company raised its full-year guidance. However, MedTech grew only 2.5%, and talc litigation expenses impacted GAAP earnings. JNJ expects future growth from pipeline advancements and strategic investments.

$CMedAI 8/10

Citigroup Inc (C) (Q3 2026) Earnings Call Highlights: Best Q3 Revenue in a Decade as Net

Citigroup reported its best Q3 revenue in a decade, but faced challenges like flat consumer cards revenue and expected market revenue declines. Expenses rose 3%, and cost of credit was $2.6 billion. CEO Jane Fraser and CFO Gonzalo Luchetti reaffirmed confidence in exceeding the full-year ROTCE target of above 11% and reiterated near-term targets of 11% to 13% for 2027-2028. The firm is investing in technology and marketing, with $3 billion in buybacks in Q3.